Paul Prefontaine
Overview
Explore the profile of Paul Prefontaine including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
911
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lapeyre L, Piret J, Rheaume C, Pons V, Uyar O, Prefontaine P, et al.
J Alzheimers Dis
. 2023 Dec;
97(1):171-178.
PMID: 38143354
Using APP/PS1 mice that overproduce amyloid-β (Aβ) peptides, we investigated whether intranasal infection with a neurovirulent clinical strain of herpes simplex virus 1 (HSV-1) before Aβ deposition could accelerate or...
2.
Piec P, Pons V, Prefontaine P, Rivest S
Cells
. 2022 Jul;
11(14).
PMID: 35883683
Methods: We studied the effect of the NOD2 receptor ligand muramyl dipeptide (MDP) on the modulation of the innate immune cells, namely patrolling monocytes and microglia. We administrated MDP once...
3.
Al-Onaizi M, Theriault P, Lecordier S, Prefontaine P, Rivest S, ElAli A
Brain Behav Immun
. 2021 Aug;
99:363-382.
PMID: 34343617
Alzheimer's disease (AD) pathology is characterized by amyloid-β (Aβ) deposition and tau hyper-phosphorylation, accompanied by a progressive cognitive decline. Monocytes have been recently shown to play a major role in...
4.
Fani Maleki A, Cisbani G, Laflamme N, Prefontaine P, Plante M, Baillargeon J, et al.
Neurotherapeutics
. 2021 Apr;
18(2):1426.
PMID: 33907979
No abstract available.
5.
Fani Maleki A, Cisbani G, Laflamme N, Prefontaine P, Plante M, Baillargeon J, et al.
Neurotherapeutics
. 2021 Jan;
18(2):889-904.
PMID: 33479802
The significance of monocytes has been demonstrated in multiple sclerosis (MS). One of the therapeutic challenges is developing medications that induce mild immunomodulation that is solely targeting specific monocyte subsets...
6.
Fani Maleki A, Cisbani G, Plante M, Prefontaine P, Laflamme N, Gosselin J, et al.
J Neuroinflammation
. 2020 Jul;
17(1):218.
PMID: 32698829
Background: Muramyl dipeptide (MDP) is a component derived from minimal peptidoglycan motif from bacteria, and it is a ligand for the NOD2 receptor. Peripheral administration of MDP converts Ly6C into...
7.
Pons V, Laflamme N, Prefontaine P, Rivest S
Front Immunol
. 2020 Feb;
11:47.
PMID: 32082318
Microglia are the innate immune cells of the CNS and their proliferation, activation, and survival have previously been shown to be highly dependent on macrophage colony-stimulating factor receptor (CSF1R). Here...
8.
Laflamme N, Prefontaine P, Lampron A, Rivest S
Curr Protoc Immunol
. 2018 Sep;
123(1):e56.
PMID: 30222250
Bone marrow transplantation is the standard of care for a host of diseases such as leukemia and multiple myeloma, as well as genetically inherited metabolic diseases affecting the central nervous...
9.
Laflamme N, Cisbani G, Prefontaine P, Srour Y, Bernier J, St-Pierre M, et al.
Front Cell Neurosci
. 2018 Jul;
12:178.
PMID: 30018535
A pathological hallmark of multiple sclerosis (MS) is myelin loss in brain white matter accompanied by compromised remyelination. Demyelinated lesions are deeply associated with oligodendrocyte apoptosis and a robust inflammatory...
10.
Cisbani G, Le Behot A, Plante M, Prefontaine P, Lecordier M, Rivest S
Brain Behav Immun
. 2018 Mar;
70:280-292.
PMID: 29545116
Stroke is the second cause of mortality worldwide and occurs following the interruption of cerebral blood circulation by cerebral vessel burst or subsequent to a local thrombus formation. Ischemic lesion...